Annual CFO
-$59.50 M
-$4.94 M-9.05%
31 December 2023
Summary:
Lexeo Therapeutics Common Stock annual cash flow from operations is currently -$59.50 million, with the most recent change of -$4.94 million (-9.05%) on 31 December 2023. During the last 3 years, it has fallen by -$56.36 million (-1798.77%). LXEO annual CFO is now -1798.77% below its all-time high of -$3.13 million, reached on 01 December 2020.LXEO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$17.81 M
+$2.35 M+11.64%
30 September 2024
Summary:
Lexeo Therapeutics Common Stock quarterly cash flow from operations is currently -$17.81 million, with the most recent change of +$2.35 million (+11.64%) on 30 September 2024. Over the past year, it has dropped by -$3.86 million (-27.65%). LXEO quarterly CFO is now -34.98% below its all-time high of -$13.19 million, reached on 30 June 2023.LXEO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$66.81 M
-$3.86 M-6.13%
30 September 2024
Summary:
Lexeo Therapeutics Common Stock TTM cash flow from operations is currently -$66.81 million, with the most recent change of -$3.86 million (-6.13%) on 30 September 2024. Over the past year, it has dropped by -$21.29 million (-46.78%). LXEO TTM CFO is now -155.52% below its all-time high of -$26.14 million, reached on 30 June 2022.LXEO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXEO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.1% | -27.6% | -46.8% |
| 3 y3 years | -1798.8% | - | - |
| 5 y5 years | - | - | - |
LXEO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1798.8% | at low | -35.0% | +53.1% | -155.5% | +19.0% |
| 5 y | 5 years | -1798.8% | at low | -35.0% | +53.1% | -155.5% | +19.0% |
| alltime | all time | -1798.8% | at low | -35.0% | +53.1% | -155.5% | +19.0% |
Lexeo Therapeutics Common Stock Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$17.81 M(-11.6%) | -$66.81 M(+6.1%) |
| June 2024 | - | -$20.15 M(+35.5%) | -$62.95 M(+12.4%) |
| Mar 2024 | - | -$14.87 M(+6.3%) | -$55.99 M(-5.9%) |
| Dec 2023 | -$59.50 M | -$13.98 M(+0.2%) | -$59.50 M(+30.7%) |
| Sept 2023 | - | -$13.95 M(+5.7%) | -$45.52 M(-34.5%) |
| June 2023 | - | -$13.19 M(-28.2%) | -$69.50 M(-15.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$18.37 M(-51.6%) | -$82.45 M(+28.7%) |
| Dec 2022 | -$54.56 M(+23.5%) | - | - |
| Sept 2022 | - | -$37.93 M(+45.1%) | -$64.08 M(+145.1%) |
| June 2022 | - | -$26.14 M | -$26.14 M |
| Dec 2021 | -$44.18 M(+1310.0%) | - | - |
| Dec 2020 | -$3.13 M | - | - |
FAQ
- What is Lexeo Therapeutics Common Stock annual cash flow from operations?
- What is the all time high annual CFO for Lexeo Therapeutics Common Stock?
- What is Lexeo Therapeutics Common Stock annual CFO year-on-year change?
- What is Lexeo Therapeutics Common Stock quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lexeo Therapeutics Common Stock?
- What is Lexeo Therapeutics Common Stock quarterly CFO year-on-year change?
- What is Lexeo Therapeutics Common Stock TTM cash flow from operations?
- What is the all time high TTM CFO for Lexeo Therapeutics Common Stock?
- What is Lexeo Therapeutics Common Stock TTM CFO year-on-year change?
What is Lexeo Therapeutics Common Stock annual cash flow from operations?
The current annual CFO of LXEO is -$59.50 M
What is the all time high annual CFO for Lexeo Therapeutics Common Stock?
Lexeo Therapeutics Common Stock all-time high annual cash flow from operations is -$3.13 M
What is Lexeo Therapeutics Common Stock annual CFO year-on-year change?
Over the past year, LXEO annual cash flow from operations has changed by -$4.94 M (-9.05%)
What is Lexeo Therapeutics Common Stock quarterly cash flow from operations?
The current quarterly CFO of LXEO is -$17.81 M
What is the all time high quarterly CFO for Lexeo Therapeutics Common Stock?
Lexeo Therapeutics Common Stock all-time high quarterly cash flow from operations is -$13.19 M
What is Lexeo Therapeutics Common Stock quarterly CFO year-on-year change?
Over the past year, LXEO quarterly cash flow from operations has changed by -$3.86 M (-27.65%)
What is Lexeo Therapeutics Common Stock TTM cash flow from operations?
The current TTM CFO of LXEO is -$66.81 M
What is the all time high TTM CFO for Lexeo Therapeutics Common Stock?
Lexeo Therapeutics Common Stock all-time high TTM cash flow from operations is -$26.14 M
What is Lexeo Therapeutics Common Stock TTM CFO year-on-year change?
Over the past year, LXEO TTM cash flow from operations has changed by -$21.29 M (-46.78%)